SG3 Management’s Verve Therapeutics VERV Stock Holding History

SG3 Management’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,000	Closed	-$137K	–	338
2022 Q3	$137K	Buy	+4,000	New	+$128K	0.02%	215

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

SG3 Management's VERV Position: Q4 2022 in Review

SG3 Management sold out of Verve Therapeutics (VERV) in Q4 2022, closing a stake of 4,000 shares — an estimated $137K sold.

SG3 Management first reported a position in VERV in Q3 2022 and held it in 1 quarter. The position peaked at $137K in Q3 2022. 123 funds tracked by Wall St. Rank hold VERV as of Q4 2022.

SG3 Management reported no remaining Verve Therapeutics position as of Q4 2022 after selling out during the quarter.
SG3 Management sold 4,000 Verve Therapeutics shares in Q4 2022, an estimated $137K.
SG3 Management first reported a position in Verve Therapeutics in Q3 2022 and held it in 1 quarter.
SG3 Management's Verve Therapeutics position peaked at $137K in Q3 2022.
123 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2022.

Based on SG3 Management's 13F filing for Q4 2022, filed 14 Feb 2023.